Close Menu

targeted sequencing

The company also said that its FoundationOne test has been accepted for parallel review as part of the Expedited Access Pathway program with the FDA and CMS.

The company shared results supporting FoundationOne's ability to estimate genome-wide mutation burdens, as well as new data linking test results to patient outcomes.

Pages